ArticleHeart rhythm O22026
Identifying independent risk factors of mortality among patients receiving a leadless pacemaker: A longitudinal retrospective study in a single center.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In certain high-risk subgroups, leadless pacemakers (LPs) have lower 2-year complications and reintervention rates than transvenous-VVI pacing. Despite this, other studies have reported higher all-cause in-hospital mortality and complications in the LP group. Many of these studies are based on claims data, which have inherent limitations. We conducted a single-center, detailed, retrospective study to examine clinical factors, including the Charlson comorbidity index (CCI), associated with higher mortality among patients receiving an LP. Objective: This study aimed to examine clinical factors, including the CCI, associated with higher mortality among patients receiving an LP. Methods: A retrospective analysis was conducted among 574 patients who received an LP between 2018 and 2022 at a quaternary care hospital. CCI was generated for each patient, and a multivariable Cox regression analysis was performed to obtain associated hazard ratios. Furthermore, we conducted logistic regression analyses to identify unique factors that affect the odds of 30-day mortality. Results: The mean CCI score in the study population was 5.30 (standard deviation 2.03). The total mortality in the study population was 26.6% (n = 146). Patients who had a CCI of >4 points had a 3-fold increase in risk of mortality compared with those who had a CCI of ≤4 points (hazard ratio 3.04; 95% confidence interval [CI] 1.70-5.42). Moreover, there was a decreased odds of survival within the first 30 days among those with a CCI of >4. Low left ventricular ejection fraction (odds ratio [OR] 2.62; 95% CI 1.05-6.56), hemoglobin (OR 2.29; 95% CI 1.10-4.77), and advanced age (OR 2.28; 95% CI 1.20-4.34) were identified as independent risk factors of early mortality. Conclusion: CCI has previously been demonstrated to be a significant predictor of mortality in patients receiving pacemakers or implantable defibrillators. In our study, we found that a CCI of >4 was independently associated with mortality. In addition, our study highlights that low left ventricular ejection fraction, hemoglobin, and advanced age are key risk factors that may predict early mortality among LP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.